Claims for Patent: 10,064,948
✉ Email this page to a colleague
Summary for Patent: 10,064,948
Title: | Implantable bio-resorbable polymer charged with fragile macromolecules |
Abstract: | The present invention relates to a macromolecule-loaded bioresorbable crosslinked polymer wherein the polymer is obtainable from the polymerization of: (i) at least one monomer of formula (I) (CH.sub.2.dbd.CR.sub.1)CO--K wherein: --K represents O--Z or NH--Z, Z representing (CR.sub.2R.sub.3).sub.m--CH.sub.3, (CH.sub.2--CH.sub.2--O).sub.m--H, (CH.sub.2--CH.sub.2--O).sub.m--CH.sub.3, (CH.sub.2).sub.m--NR.sub.4R.sub.5 with m representing an integer from 1 to 30; --R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 independently represent H or a C1-C6 alkyl; and (ii) at least one bio-resorbable block copolymer cross-linker, and wherein the macromolecule is chosen in the group consisting of proteins and nucleic acids. |
Inventor(s): | Moine; Laurence (Saint Cloud, FR), Laurent; Alexandre (Courbevoie, FR), Wassef; Michel (Paris, FR), Bedouet; Laurent (Paris, FR), Louguet; Stephanie (Bordeaux, FR), Verret; Valentin (Gentilly, FR), Servais; Emeline (Janvry, FR) |
Assignee: | Occlugel (Jouy en Josas, FR) Centre National de la Recherche Scientifique (CNRS) (Paris, FR) Assistance Publique Hopitaux de Paris (Paris, FR) Universite Paris Diderot--Paris 7 (Paris, FR) |
Application Number: | 14/003,528 |
Patent Claims: | 1. A macromolecule-loaded bioresorbable crosslinked polymer wherein the polymer is obtainable from the polymerization of: (i) at least one monomer of formula (I)
(CH.sub.2.dbd.CR.sub.1)CO--K (I) wherein: K represents O--Z or NH--Z, Z representing (CR.sub.2R.sub.3).sub.m--CH.sub.3, (CH.sub.2--CH.sub.2--O).sub.m--H, (CH.sub.2--CH.sub.2--O).sub.m--CH.sub.3, (CH.sub.2).sub.m--NR.sub.4R.sub.5 with m representing an
integer from 1 to 30; R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 independently represent H or a C.sub.1-C.sub.6 alkyl; and (ii) at least one bio-resorbable block copolymer cross-linker, wherein the bio-resorbable block copolymer cross-linker is
linear and selected from the group consisting of polyethylene glycol (PEG), poly-lactic acid (PLA), poly-glycolic acid (PGA), poly-lactic-glycolic acid (PLGA) and poly(caprolactone) (PCL); and is of the following formula (II):
(CH.sub.2.dbd.CR.sub.7)CO--(X.sub.n).sub.j--PEG.sub.p-Y.sub.k--CO--(CR.su- b.8.dbd.CH.sub.2) (II) wherein: R.sub.7 and R.sub.8 independently represent H or a C.sub.1-C.sub.6 alkyl; X and Y independently represent PLA, PGA, PLGA or PCL; n, p, and k
respectively represent the degree of polymerization of X, PEG, and Y, n and k independently being integers from 1 to 150, and p being an integer from 1 to 100; j represents 0 or 1; and (iii) at least one chain transfer agent, wherein the at least one
chain transfer agent is a cycloaliphatic or an aliphatic thiol having from 2 to 24 carbon atoms, and wherein the loaded macromolecule is selected from the group consisting of proteins and nucleic acids.
2. The polymer of claim 1, wherein the bio-resorbable block copolymer cross-linker is of a formula selected from the group consisting of: (CH.sub.2.dbd.CR.sub.7)CO-PLA.sub.n-PEG.sub.p-PLA.sub.k-CO-- (CR.sub.8.dbd.CH.sub.2), (CH.sub.2.dbd.CR.sub.7)CO-PGA.sub.n-PEG.sub.p-PGA.sub.k-CO-- (CR.sub.8.dbd.CH.sub.2), (CH.sub.2.dbd.CR.sub.7)CO-PLGA.sub.n-PEG.sub.p-PLGA.sub.k-CO-- (CR.sub.8.dbd.CH.sub.2), (CH.sub.2.dbd.CR.sub.7)CO-PEG.sub.p-PLA.sub.k-CO-- (CR.sub.8.dbd.CH.sub.2), (CH.sub.2.dbd.CR.sub.7)CO-PEG.sub.p-PGA.sub.k-CO-- (CR.sub.8.dbd.CH.sub.2), and (CH.sub.2.dbd.CR.sub.7)CO-PEG.sub.p-PLGA.sub.k-CO-- (CR.sub.8.dbd.CH.sub.2); wherein R.sub.7, R.sub.8, n, p and k are as defined in claim 1. 3. The polymer of claim 1, wherein the monomer of formula (I) is selected from the group consisting of sec-butyl acrylate, n-butyl acrylate, t-butyl acrylate, t-butyl methacrylate, methylmethacrylate, N-dimethyl-aminoethyl(methyl)acrylate, N,N-dimethylaminopropyl-(meth)acrylate, t-butylaminoethyl (methyl) acrylate, N,N-diethylaminoacrylate, acrylate terminated poly(ethylene oxide), methacrylate terminated poly(ethylene oxide), methoxy poly(ethylene oxide) methacrylate, butoxy poly(ethylene oxide) methacrylate, acrylate terminated poly(ethylene glycol), methacrylate terminated poly(ethylene glycol), methoxy poly(ethylene glycol) methacrylate, butoxy poly(ethylene glycol) methacrylate, and poly(ethylene glycol) methyl ether methacrylate. 4. A macromolecule-loaded bioresorbable crosslinked polymer wherein the polymer is obtainable from the polymerization of: (i) at least one monomer of formula (I) (CH.sub.2.dbd.CR.sub.1)CO--K (I) wherein: K represents O--Z or NH--Z, Z representing (CR.sub.2R.sub.3).sub.m--CH.sub.3, (CH.sub.2--CH.sub.2--O).sub.m--H, (CH.sub.2--CH.sub.2--O).sub.m--CH.sub.3, (CH.sub.2).sub.m--NR.sub.4R.sub.5 with m representing an integer from 1 to 30; R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 independently represent H or a C.sub.1-C.sub.6 alkyl; (ii) at least one bio-resorbable block copolymer cross-linker, wherein the bio-resorbable block copolymer cross-linker is linear and presents (CH.sub.2.dbd.(CR.sub.6))--groups at both its extremities, wherein R.sub.6 independently represents H or a C.sub.1-C.sub.6 alkyl; (iii) at least one chain transfer agent, wherein the at least one chain transfer agent is a cycloaliphatic or an aliphatic thiol having from 2 to 24 carbon atoms, and (iv) further at least one cyclic monomer having an exo-methylene group of formula (III): ##STR00005## wherein: R.sub.6, R.sub.7, R.sub.8 and R.sub.9 represent independently H or a C.sub.5-C.sub.7 aryl group or R.sub.7 and R.sub.8 are absent and R.sub.7 and R.sub.8 form together with the carbon atom on which they are bonded a C.sub.5-C.sub.7 aryl group; i and j represent independently an integer from 0 to 2; and X represents either O or X is not present and in this latter case, CR.sub.6R.sub.7 and CR.sub.8R.sub.9 are linked via a single bond C--C; and wherein the loaded macromolecule is selected from the group consisting of proteins and nucleic acids. 5. The polymer of claim 4, wherein the at least cyclic monomer of formula (III) is selected from the group consisting of 2-methylene-1,3-dioxolane, 2-methylene-1,3-dioxane, 2-methylene-4-phenyl-1,3-dioxolane, 2-methylene-1,3-dioxepane, 5,6-benzo-2-methylene-1,3dioxepane and 2-methylene-1,3,6-trioxocane. 6. A macromolecule-loaded bioresorbable crosslinked polymer wherein the polymer is obtainable from the polymerization of: (i) at least one monomer of formula (I) (CH.sub.2.dbd.CR.sub.1)CO--K (I) wherein: K represents O--Z or NH--Z, Z representing (CR.sub.2R.sub.3).sub.m--CH.sub.3, (CH.sub.2--CH.sub.2--O).sub.m--H, (CH.sub.2--CH.sub.2--O).sub.m--CH.sub.3, (CH.sub.2).sub.m--NR.sub.4R.sub.5 with m representing an integer from 1 to 30; R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 independently represent H or a C.sub.1-C.sub.6 alkyl; (ii) at least one bio-resorbable block copolymer cross-linker, wherein the bio-resorbable block copolymer cross-linker is linear and presents (CH.sub.2.dbd.(CR.sub.6))--groups at both its extremities, wherein R.sub.6 independently represents H or a C.sub.1-C.sub.6 alkyl; (iii) at least one chain transfer agent, wherein the at least one chain transfer agent is a cycloaliphatic or an aliphatic thiol having from 2 to 24 carbon atoms, optionally at least one cyclic monomer having an exo-methylene group, and at least one further monomer which is a charged, ionisable, hydrophilic, or hydrophobic monomer of the following formula (V): (CH.sub.2.dbd.CR.sub.11)CO-M-F (V) wherein: R.sub.11 represents H or a C.sub.1-C.sub.6 alkyl; M represents a single bond or a linker moiety having from 1 to 20 carbon atoms; F represents a charged, ionisable, hydrophilic, or hydrophobic group having 100 atoms at the most; wherein the optional at least one cyclic monomer having an exo-methylene group is one of formula (III): ##STR00006## wherein: R.sub.6, R.sub.7, R.sub.8 and R.sub.9 represent independently H or a C.sub.5-C.sub.7 aryl group or R.sub.6 and R.sub.9 are absent and R.sub.7 and R.sub.8 form together with the carbon atom on which they are bonded a C.sub.5-C.sub.7 aryl group; i and j represent independently an integer from 0 to 2; and X represents either O or X is not present and in this latter case, CR.sub.6R.sub.7 and CR.sub.8R.sub.9 are linked via a single bond C--C, and wherein the loaded macromolecule is selected from the group consisting of proteins and nucleic acids. 7. The polymer of claim 6, wherein F is selected from the group consisting of COOH, COOH, COO.sup.-, SO.sub.3H, SO.sub.3.sup.-, PO.sub.4H.sub.2, PO.sub.4H.sup.-, PO.sub.4.sup.2-, NR.sub.9R.sub.10, NR.sub.9R.sub.12R.sub.10.sup.+, R.sub.9, R.sub.12 and R.sub.10 independently representing H or a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.20 alkyl group, a C.sub.5-C.sub.20 aryl group, a (5-30-members) heteroaryl group containing an heteroatom selected from the group consisting of O, N or S, a O--C.sub.5-C.sub.20 aryl group and a O-(5-30-members)heteroaryl group, a crown ether, and a cyclodextrin. 8. The polymer of claim 1, wherein the loaded macromolecule is selected from the group consisting of enzymes, antibodies, cytokines, growth factor, coagulation factors, hormones, plasmids, antisense oligonucleotides, siRNA, ribozymes, DNAzymes, aptamers, cationic polymers for nucleic acid loading, anti-inflammatory proteins, bone morphogentic proteins, angiogenic factors, vascular endothelial growth factors, TGF-beta, and inhibitors of angiogenesis. 9. The polymer of claim 1, which is in the form of a film, a foam, a particle, a lump, a thread, or a sponge. 10. A pharmaceutical composition comprising at least one macromolecule loaded bioresorbable crosslinked polymer of claim 1, in association with a pharmaceutically acceptable carrier. 11. An injectable pharmaceutical composition comprising (a) a macromolecule-loaded bioresorbable crosslinked polymer obtainable as described in claim 1 having a spherical shape of a diameter of between 50 and 500 .mu.m and a resorption time of between 2 days to 3 weeks; (b) a macromolecule-loaded bioresorbable crosslinked polymer obtainable as described in claim 1 having a spherical shape of a diameter of between 50 and 500 .mu.m and a resorption time of between one to 3 months; and (c) at least a pharmaceutically acceptable excipients. 12. The composition of claim 11, wherein the spherical particles of macromolecule-loaded bioresorbable crosslinked polymers (a) and (b) do not have the same diameter. 13. An implant containing the macromolecule-loaded bioresorbable crosslinked polymer of claim 1. 14. The implant of claim 13, for implantation into tissues, brain, spinal cord, bones defects, internal anatomical spaces, body cavities, ducts and vessels. 15. The macromolecule-loaded bioresorbable crosslinked polymer of claim 1, wherein the at least one chain transfer agent is a cycloaliphatic or an aliphatic thiol having from 2 to 24 carbon atoms, and having a further functional group selected from the group consisting of amino, hydroxy and carboxy. 16. The polymer of claim 5 wherein the at least cyclic monomer of formula (III) is selected from the group consisting of 2-methylene-1,3-dioxepane, 5,6-benzo-2-methylene-1,3dioxepane and 2-methylene-1,3,6-trioxocane. 17. The polymer of claim 8 wherein the loaded macromolecule is selected from the group consisting of growth hormones, poly(allylamine hydrochloride), polydiallyldimethylammonium, polyethylenimine, poly(L-lysine), polydopamine, chitosan, polyamidoamine dendrimers, infliximab, rilonacept, fibroblast growth factors, bevacizumab and pegaptanib. 18. The composition of claim 12 wherein the diameter of the spherical particles of polymer (a) is of between 100 and 300 .mu.m and the diameter of the spherical particles of polymer (b) is of between 300 and 500 .mu.m. |
Details for Patent 10,064,948
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | August 24, 1998 | ⤷ Try for Free | 2031-03-09 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Try for Free | 2031-03-09 |
Kiniksa Pharmaceuticals (uk), Ltd. | ARCALYST | rilonacept | For Injection | 125249 | February 27, 2008 | ⤷ Try for Free | 2031-03-09 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |